Royalty Report: Cancer, Diagnostic, Drugs – Collection: 6345

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Cancer
  • Diagnostic
  • Drugs
  • Disease
  • Biotechnology
  • Medical
  • Diagnostic Substances
  • Device
  • Technical Know How
  • Software
  • Medical Info
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6345

License Grant
The Company grants an exclusive, worldwide, royalty-bearing License, with the right to subLicense, to make, have made, use, sell and import Licensed Products, which includes finished products used for the detection of the Company’s proprietary prostate cancer biomarkers in both urine and biopsied prostate tissue for differentiating clinically significant prostate cancer from other prostate conditions, and to use Patent Rights and Know-How covering the prostate cancer biomarkers.
License Property
Licensed Product(s) shall mean finished products consisting of one or more nucleic acid detection reagents for the assay of one or more Prostate Marker(s) for use in the Field, the manufacture, use, sale or importation of which, but for the rights granted herein, would infringe a Valid Claim within Patent Rights.

U.S.
7,117,188
Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S.
12/025,724
Biomarkers Upregulated in Prostate Cancer

U.S.
12/242,264
Biomarkers Overexpressed in Prostate Cancer

U.S.
12/327,823
Methods for Screening, Predicting and Monitoring Prostate Cancer

U.S.
12/349,437
Methods for Screening, Predicting and Monitoring Prostate Cancer

Field of Use
Field shall mean the use of a molecular diagnostic assay using the Licensed Prostate Markers in in vitro diagnostics relating to prostate cancer, including the detection of the presence or risk of prostate cancer, or the selection of therapy, or in a Research Application related to prostate cancer.

IPSCIO Record ID: 3802

License Grant
Licensor hereby grants an exclusive license with the right to grant sublicenses to Affiliates, and, upon prior approval by Licensor, to third parties under the Licensed Technology to import, make, have made, use and sell any Licensed Product in the Field of Use within the Licensed Territory.
License Property
Licensor has certain patent rights and technology covering genomic biomarkers related to prostate cancer.

The Licensor announced an alliance and licensing Agreement with the Licensee for development of a new molecular diagnostic test for prostate cancer based on the Licensor's discovered prostate cancer biomarker signature.  The parties have successfully completed all phases of the clinical trial process with the hope of achieving the statistical significance necessary to validate the ability to commercialize a test.

The agreement covers a unique 4-gene test that may enhance the early detection and staging of prostate cancer, thereby helping doctors make better decisions on diagnosing this disease and determining more appropriate, patient specific treatment plans. Licensor will lead the research effort through the application of its patent protected SVM technology. Licensee will have a right of first refusal to license and commercialize any subsequent cancer tests resulting from licensor's development endeavors. Licensee anticipates that it will begin validation work on the cancer marker immediately and follow with appropriate clinical studies to support the preliminary findings. Once the clinical studies are completed, licensee will seek the necessary regulatory approvals and clearances.

U.S. 7,117,188 Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S. 2007/0092917 Biomarkers for Screening, Predicting, and Monitoring Prostate Disease

Field of Use
'Field of Use' shall mean diagnostic tests using gene biomarkers for differentiating clinically significant prostate cancer from other prostate conditions using biopsied prostate tissue.

IPSCIO Record ID: 315834

License Grant
For the Licensed Technology, Licensor grants a non-exclusive license under the Licensed Technology to make, have made, use, sell, offer for sale and import Licensed Uses in the Territory in the Field.

For the Research, Licensee shall perform primary testing associated with a validation study of its laboratory -developed test using the Licensed Technology in connection with MD Anderson Cancer Center or an equivalent academic cancer center (with the exception of tissue biopsy) including expression testing, the PSA and send-out of the PCA-3, the Validation Study.  Licensee shall have the right to perform research on remnants after all testing required for the Validation Study is completed, and will be provided reasonable access to the patient data related to the applicable samples.  Licensor shall obtain IRB approval for the study with MD Anderson Cancer Center by February 28, 2009 or, with an equivalent academic institution by June 30, 2009.

For the Purchasing Rights, upon issuance of FDA clearance or approval of an in vitro diagnostic kit using the Licensed Technology (IVD Kit), Licensee shall have the obligation to purchase IVD Kits for reference laboratory use from Licensor’s designated manufacturer or distributor pursuant to a purchasing agreement between Licensee and the applicable manufacturer or distributor, provided however that Licensor shall negotiate to cause such manufacturer or distributor to provide Most Favored Terms to Licensee.

License Property
Licensor has rights in the Licensed Technology covering genomic biomarkers related to prostate cancer.  Licensor is a machine learning company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery.

The patents include
Method of Identifying Patterns in Biological Systems and Uses Thereof;
Biomarkers Overexpressed in Prostate Cancer;
Biomarkers Upregulated in Prostate Cancer; and,
Methods for Screening, Predicting and Monitoring Prostate Cancer.

Field of Use
Field shall mean clinical diagnostic applications using biomarkers in urine for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of in vitro diagnostic kits.

Licensees focus is developing a test for and performing clinical laboratory diagnostic testing using gene biomarkers detected in patient urine samples for differentiating clinically significant prostate cancer from other prostate conditions.

IPSCIO Record ID: 6506

License Grant
Licensor grants a non-exclusive license, with the right to grant sublicenses to Affiliates, and, upon prior approval by Licensor, to third parties under the Licensed Technology to import, make, have made, use and sell any Licensed Product with respect to both the commercial reference laboratory field and the academic and research fields.
License Property
The Parties are working on development of a new molecular diagnostic test for prostate cancer based on our discovered prostate cancer biomarker signature.

7,117,188 Method of Identifying Patterns in Biological Systems and Uses Thereof
U.S. 2007/0092917 Biomarkers for Screening, Predicting, and Monitoring Prostate Disease

IPSCIO Record ID: 26501

License Grant
The Canadian Licensor hereby grants to Licensee a worldwide, exclusive license and sublicense (including the right to grant sublicenses) in the Field under the Licensed IP Rights to research, develop, make, have made, use, offer for sale, sell and import Licensed Products, and practice Licensed Methods, in each case for the detection and/or measurement of PCA3(DD3) as a marker for the diagnosis monitoring, prognosis, or drug susceptibility of prostate cancer.
License Property
The Licensor owns or has intellectual property rights with respect to the PCA3(DD3) gene (as defined below) and certain related technology.

APTIMA(R) Technology shall mean all technology reasonably necessary to make or use Licensee's APTIMA generation of amplified nucleic acid assays, including Target Capture (TC), Transcription-Mediated Amplification (TMA), Hybridization Protection Assay (HPA) and Dual Kinetic Assay (DKA) technologies, each to the extent in each case that Licensee has a right to license or sublicense.

The technology is a diagnostic technology (genetic) for the early warning of prostate cancer.

The licensor's (Quebec, Canada) urine test (PCA3) to detect the genetic marker of prostate cancer is now being developed by the licensee based in San Diego, and after more clinical trials a new version will hit the market by year end (2005).

Field of Use
Field shall mean the detection and/or measurement of PCA3(DD3) as (a) a marker for the diagnosis, monitoring, prognosis, or drug susceptibility of prostate cancer; and/or (b) a marker for cancer (without limitation).  The Field shall not include the use of any assay in drug discovery.

IPSCIO Record ID: 7158

License Grant
Licensor hereby grants to Licensee and its Affiliates, and Licensee accepts the licenses under the Licensed Technology to exclusively use, develop, make, have made, sell, offer to sell, modify, import and otherwise commercially exploit the Licensed Uses and the Licensed Products in the Licensed Territory including, but not limited to, as follows
(1) an exclusive license for the use of the SVM Technology and the Licensed Patents in the Field in the Licensed Territory relating to Licensed Uses and Licensed Products; and

(2) an exclusive license to the Licensed Know-How in the Field in the Licensed Territory, including access to and use of the Computer Software that has been developed by or for Licensor or will be developed by or for the Licensor that may be applicable to Licensed Uses or Licensed Products; and

(3) an exclusive license for the use of Licensed Products in the Licensed Territory.
Sublicense Rights. Licensee may grant sublicenses under any of the licenses granted herein, to import, develop, make, have made, use, modify, offer for sale, and/or sell Licensed Products within the Field.

License Property
LICENSOR is the owner of intellectual property, including patents, pending and issued, and know-how relating to support vector machine and other machine learning technologies which is included within the “SVM Technology” (as defined below), based upon which it has developed, or is engaged in developing, applications including, inter alia, digital image analysis and interpretation, biomarker discovery, and gene/gene product-based and protein-based diagnostic, prognostic and predictive tests.

“SVM Technology” shall mean all technology and ownership claims related to support vector machines and other pattern-recognition algorithms (“SVM”), SVM-Recursive Feature Elimination (“RFE”), and Fractal Genomic Modelling (“FGM”) included in the Licensed Technology.

Licensor owns the Licensed Technology (as defined below), which includes inter alia, coverage of genomic biomarkers related to prostate cancer, pancreatic cancer, colon cancer and other cancers as well as certain interpretation methodologies and software associated with automated image analysis for cytogenetics and flow cytometry testing.

“IVD Test Kit” shall mean any kit or instrument manufactured for sale to third parties, which includes reagents and other supplies that enables such third party purchasers to perform in vitro diagnostic tests on biological samples or any instrument used therewith; provided that, any such IVD Test Kit must be approved by the U.S. Food and Drug Administration (“FDA”) for sales of the IVD Test Kit in the United States, or be approved by any other foreign regulatory bodies for sales of the IVD Test Kit in countries other than the United States. Notwithstanding the foregoing, any instruments sold in conjunction with or pursuant to Licenses E and F described in Sections 1.12.4 and 1.12.5 are excluded from the definition of IVD Test Kit.

“Laboratory Developed Test” shall mean any test, process or procedure used to test or assay any type of patient biological sample, the results of which would then normally be entered into the medical record of the patient providing such biological sample; provided, however, any test, process or procedure performed using an IVD Test Kit shall not be considered to be a Laboratory Developed Test.

“Plasma Prostate Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in blood plasma for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Plasma Prostate Cancer Test is identified as “License B”.

“Pancreatic Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in any type of biological sample for differentiating clinically significant pancreatic cancer from other pancreatic conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Pancreatic Test is identified as “License C”.

“Colon Cancer Test” shall mean any Laboratory Developed Test using genes, gene products or other biomarkers for differentiating clinically significant colon cancer from other colon conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Colon Cancer Test is identified as “License D”.

“Cytogenetics Interpretation System” shall mean any interpretive software and related technology for computer-aided karyotype analysis for genetic screening and detection of chromosomal abnormalities. For reference purposes, the license granted for the Cytogenetics Interpretation System is identified as “License E”.

“Flow Cytometry Interpretation System” shall mean interpretive software and related technology for computer-aided analysis of flow cytometry tests. For reference purposes, the license granted for the Flow Cytometry Interpretation System is identified as “License F”.

“Urine Prostate Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in urine samples for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Urine Prostate Cancer Test is identified as “License G”.

“Tissue Prostate Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in tissue samples for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Tissue Prostate Cancer Test is identified as “License H”.

Licensed Patents
Patent/Application No.
Title
Filing Date/
Expires

Issue Date

Patent/Application No.
Title
Filing Date/
Expires

Issue Date

U.S. Patent No. 6,128,608
Enhancing Knowledge Discovery Using Multiple Support Vector Machines
05-01-1999/
5/1/2019

10/3/2000

U.S. Patent No. 6,157,921
Enhancing Knowledge Discovery Using Support Vector Machines in a Distributed Network Environment
05-01-1999/
5/1/2019

12/5/2000

U.S. Patent No. 6,427,141
Enhancing Knowledge Discovery Using Multiple Support Vector Machines.
05-09-2000/
5/1/2019

7/30/2002

U.S. Patent No. 6,658,395
Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.
05-24-2000/
5/1/2019

12/2/2003

U.S. Patent No. 6,714,925
System for Identifying Patterns in Biological Data Using a Distributed Network.
08-07-2000/
5/1/2019

3/30/2004

U.S. Patent No. 6,760,715
Enhancing Biological Knowledge Discovery Using Multiple Support Vector Machines.
08-07-2000/
5/1/2019

7/6/2004

U.S. Patent No. 6,789,069
Method of Identifying Patterns in Biological Systems and Method of Uses.
08-07-2000/
4/13/2020

9/7/2004

U.S. Patent No. 6,882,990
Method of Identifying Biological Patterns Using Multiple Data Sets.
08-07-2000/
5/1/2019

4/19/2005

U.S. Patent No. 6,944,602
Spectral Kernels for Learning Machines
03-01-2002/
2/19/2023

9/13/2005

U.S. Patent No. 6,996,549
Computer-Aided Image Analysis
01-23-2002/
4/21/2021

2/7/2006

U.S. Patent No. 7,117,188
Methods of Identifying Patterns in Biological Systems and Uses Thereof
01-24-2002/
3/9/2022

10/3/2006

U.S. Patent No. 7,299,213
Method of Using Kernel Alignment to Extract Significant Features from a Large Dataset
09-12-2005/
3/1/2022

11/20/2007

U.S. Patent No. 7,318,051
Methods for Feature Selection in a Learning Machine
11-18-2003/
2/25/2021

1/8/2008

U.S. Patent No. 7,353,215
Kernels and Methods for Selecting Kernels for Use in Learning Machines
11-07-2003/
1/27/2023

4/1/2008

U.S. Patent No. 7,383,237
Computer-Aided Image Analysis
02-06-2006/
11/4/2019

6/3/2008

U.S. Patent No. 7,444,308
Data Mining Platform for Bioinformatics and Other Knowledge Discovery
12-15-2003/
5/28/2022

10/28/2008

U.S. Patent No. 7,475,048
Pre-Processed Feature Ranking for a Support Vector Machine
05-07-2004/
7/22/2021

1/6/2009

U.S. Patent No. 7,542,947
Data Mining Platform for Bioinformatics and Other Knowledge Discovery
10-30-2007/
5/20/2022

6/2/2009

U.S. Patent No. 7,542,959
Feature Selection Method Using Support Vector Machine Classifier
08-21-2007/
8/7/2020

6/2/2009

U.S. Patent No.  7,617,163
Kernels and Kernel Methods for Spectral Data
10-09-2002/

11/10/2009

U.S. Patent No. 7,624,074
Methods for Feature Selection in a Learning Machine
10-30-2007/
8/7/2020

11/24/2009

U.S. Patent No. 7,676,442
Selection of Features Predictive of Biological Conditions Using Protein Mass Spectrographic Data
10-30-2007/
8/7/2020

3/9/2010

U.S. Patent No. 7,788,193
Kernels and Methods for Selecting Kernels for Use in Learning Machines
10-30-2007/
8/6/2023

8/31/2010

U.S. Patent No. 7,797,257
System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source
10-31-2007/
7/28/2020

9/14/2010

U.S. Patent No. 7,805,388
Method for Feature Selection in a Support Vector Machine Using Feature Ranking
10-30-2007/
8/7/2020

9/28/2010

U.S. Patent No. 7,890,445
Model Selection for Cluster Data Analysis
10-30-2007/
6/8/2024

12/15/2011

U.S. Patent No.  7,921,068
Data Mining Platform for Knowledge Discovery from Heterogeneous Data Types and/or Heterogeneous Data Sources
10-30-2007/
5/20/2022

4/5/2011

U.S. Patent No.  7,970,718
Method for Feature Selection and for Evaluating Features Identified as Significant for Classifying Data
09-26-2010/
1/24/2022

6/28/2011

U.S. Patent No.  8,008,012
Biomarkers Downregulated in Prostate Cancer
09-30-2008/
1/13/2026

8/30/2011

U.S. Patent  No. 8,095,483
Support Vector Machine-Recursive Feature Elimination (SVM-RFE)
12-01-2010/
8/7/2020

1/10/2012

U.S. Patent Publ. No. 2005/0165556
Colon Cancer-Specific Biomarkers
01-11-2005/
08-07-2020 + PTA

U.S. Patent Publ. No. 2010/0256988
System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source
06-11-2010/
5/1/2019

U.S. Patent Publ. No. 2011/0106735
Recursive Feature Elimination Method Using Support Vector Machines
11/11/2010
08-07-2020 + PTA

U.S.Patent Publ. No. 2010/0318482
Kernels for Identifying Patterns in Datasets Containing Noise or Transformation Invariances
08-25-2010/
05-07-2022 + PTA

U.S.Patent Publ. No. 2011/0184896
Method for Visualizing Feature Ranking of a Subset of Features for Classifying Data Using a Support Vector Machine
04-04-2011/
05-20-2022  PTA

U.S. Patent Publ. No. 2010/0205124
Support Vector Machine-Based Method for Analysis of Spectral Data
02-04-2010/
08-07-2020 + PTA

U.S.Patent Publ. No. 2011/0125683
Identification of Co-Regulation Patterns by Unsupervised Cluster Analysis of Gene Expression Data
02-02-2011/
05-17-2022 + PTA

U.S. Patent Publication No. 2009/0204557
Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines
02-08-2009/
02-08-2029 + PTA

U.S. Patent Publication No. 2008/0050836
Biomarkers for Screening, Predicting, and Monitoring Benign Prostate Hyperplasia
07-26-2007/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0215024
Biomarkers Upregulated in Prostate Cancer
02-04-2008/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0286240
Biomarkers Overexpressed in Prostate Cancer
09-30-2008/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0215058
Methods for Screening, Predicting and Monitoring Prostate Cancer
12-04-2008/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0226915
Methods for Screening, Predicting and Monitoring Prostate Cancer
01-06-2009/
11-14-2025 + PTA

U.S.Patent Publication No.  2011/0312509
Biomarkers Downregulated in Prostate Cancer
08-29-2011/
11-14-2025 + PTA

U.S. Patent No. 6,920,451
Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets
01-19-2001/
6/9/2021

7/19/2005

U.S. Patent No. 7,366,719
Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets
10-06-2004/

4/29/2008

Field of Use
“Field” or “Field of Use” shall mean the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology, and digital image analysis, excluding non-pathology-related radiologic and photographic image analysis, relating to the development, marketing, production or sale of any Laboratory Developed Tests or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer; provided, however, the manufacture and sale of IVD Test Kits for sales to third parties and the melanoma screening system and methods described in the patent applications listed in Exhibit D are specifically excluded from the Field or Field of Use; and provided further that the foregoing exclusion of “and breast cancer” immediately prior to the first proviso of this section shall be in effect only so long as the License Agreement among and between LICENSOR.

The Licensee is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing. The Licensee's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, The Licensee services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States.

IPSCIO Record ID: 4246

License Grant
Licensor grants, subject to the terms of this Agreement, to Licensee a worldwide, perpetual and exclusive license to make, have made, use and create improvements to the P&O Technology, Know-How and Improvements thereto to make, have made, use, market and sell Licensed Products.
License Property
Licensee shall have the right to grant sublicenses under the license granted herein.

Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How .

Field of Use
P&O Technology shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that Biotherapies cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.

IPSCIO Record ID: 223141

License Grant
The German Licensor hereby grants to Licensee an exclusive license (including the right to grant sublicenses) under the Licensed Patent Rights to conduct research and to develop, make, use, offer for sale, sell and import Licensed Products and to provide Services in the Territory.
License Property
Licensed Patent Rights shall mean (a) those certain patent applications and patents listed hereto; (b) all patents that have issued or in the future issue from such foregoing patent applications, including utility, model and design patents and certificates of invention; (c) all patents that have issued or in the future issue from any patent application that claims priority from, or common priority with, any of the foregoing patent applications, including utility, model and design patents and certificates of invention; and (d) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such foregoing patent
applications and patents.

W003023057 (PCT /EP02/05489) – Method and Diagnosis Kit for Selection and/or for Qualitative and/or Quantitative Detection of Cells

Licensed Products shall mean in-vitro diagnostic assays to isolate, detect, identify, quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care, the  manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the AdnaGen Patent Rights.

Field of Use
This agreement pertains to the medical industry relating to certain technology concerning the qualitative and quantitative detection of cells which may be useful in connection with nucleic acid diagnostic assays. The diagnostic indicators are used for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care.

'Group 1 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of kidney cancer, cervical cancer, and/or ovarian cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

'Group 2 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of lung cancer, colon cancer, and/or breast cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

IPSCIO Record ID: 5426

License Grant
Licensor grants, subject to the terms of this Agreement, to License a worldwide, perpetual and exclusive sublicense to make, use and sell the Protein and Antibodies solely for use with the Mammastatin Serum Assay and  to make, have made, use and sell the Mammastatin Serum Assay and Improvements thereto.

Licensor grants, subject to the terms of this Agreement, to GBI a worldwide, perpetual and non-exclusive sublicense to make, use and create Improvements to Proteins and Antibodies solely in the research, development and sale of additional antibodies and/or diagnostic assays solely for the diagnosis of breast, prostate and/or ovarian cancers.  Also includes  to make, have made, use and create Improvements to the Mammastatin Serum Assay and the Know-How solely in the research, development and sale of Additional Products.

License Property
The Mammastatin Serum Assay is a test to measure Mammastatin levels in the serum of healthy women and breast cancer patients. This assay has been performed in two different formats with different antibody formats.

Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How

P&O TECHNOLOGY shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that BIOTHERAPIES cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.

IPSCIO Record ID: 238982

License Grant
University hereby grants to Licensee an exclusive, worldwide right and license, with the right to grant Sublicenses and to permit Sub-sublicenses to practice under and use the Licensed Patents and the Licensed Technology to make, have made, use, market, sell, have sold, import, distribute, and offer for sale any Licensed Product, Licensed Process or Generic Product. University hereby agrees, subject to the terms and conditions herein contained, that the term 'exclusive' means that University shall not grant any other license to any third party or take any action inconsistent with the rights granted to Licensee under this Agreement relating to the Licensed Patents or Licensed Technology.
License Property
Licensed Patents shall mean
6,265,448 – Method for chemoprevention of prostate cancer
6,413,533 – Method for chemoprevention of prostate cancer
6,413,534 – Method for chemoprevention of prostate cancer
6,410,043 – Method for chemoprevention of prostate cancer
6,413,535 – Method for chemoprevention of prostate cancer

Licensed Technology shall mean any technology, trade secrets, methods, processes, know-how, show-how, data, information, or results relating to the patent applications, developed by the Contributors and owned by University, including the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent or pharmaceutical preparation comprising an anti-estrogen or SERM, including, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis.

Field of Use
Patents relate to toremifene for the reduction in the incidence of prostate cancer in men with high grade PIN and its composition of matter and method of use patents and patent applications relating to Andarine to market, distribute and sell licensed products.

IPSCIO Record ID: 369284

License Grant
University grants Licensee and its affiliated companies and exclusive License under the Licensed Patents and a non-exclusive license under the know-how in the field of use to make, have made, use, sell, offer to sell and import Licensed Products and perform Licensed Services in the Licensed Territory. If any affiliated company exercises rights under this Agreement, such affiliated company shall be bound by all terms and conditions of this Agreement, including but not limited to indemnity and insurance provisions and royalty payments. In addition, Licensee shall remain fully liable to University for all acts and obligations of affiliated company such that acts of the affiliated company shall be considered acts of the Licensee. Exclusive refers to Licensed Patents only. Know-how, data and other materials licensed are provided on a non-exclusive basis only.
License Property
Licensor Inventions related to 'Multiple Novel Androgen Receptor Variants as Biomarkers and Therapeutic Targets for Androgen Refractory Human Prostate Cancer' and 'Methods and Compositions Related to Prostate Cancer Therapeutics'.

Licensed Patent means (a) U.S. Provisional Patent Application Nos. 62/041,368, 61/124,359. 61/124,328, 61/114,153 International Patent Application No. PCT/US2009/02392 U.S. Patent Application No. 12/988,299, Canadian Patent Application No. 2,721,506 and European Patent Application No. 09733012.0 and the inventions disclosed and claimed therein

Technology related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company’s lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.

Field of Use
Inventions related to certain assays to identify androgen receptor variants for use as a companion diagnostic with galeterone.

Galeterone is a highly selective, multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The pathway is ordinarily activated by the binding of male hormones, or androgens, such as testosterone and the more potent androgen dihydrotestosterone, or DHT, to the ligand binding domain of androgen receptors in prostate cancer cells. Galeterone disrupts the activation of the pathway through multiple mechanisms of action.

Field of Use companion diagnostic for Galeterone (excluding commercial sale as research reagent).

IPSCIO Record ID: 5297

License Grant
Licensor hereby grants the right to use MoAb 7E11-C.5.3 solely for such purposes.
License Property
The term 'MoAb 7E11 shall mean and collectively include that certain antibody to PSMA known as MoAb 7E11-C5, which such antibody is claimed in United States Patent No 5,162,504, granted November 10, 1992, and entitled 'Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostate Cancer Patients.'  One subclone of MoAb 7E11 is MoAb 7E11-C5.3.  To enable the licensee to utilize MoAb 7E11-C 5.3 in connection with the development, manufacturing, testing, or conducting quality control tests on Licensed Products and to practice Licensed Processes.
Field of Use
The term 'PSMA' shall mean prostate specific membrane antigen and shall include the PSMA protein.

The term 'PSMP' shall mean prostate specific membrane peptides which shall include any peptide sequence appearing within the PSMA protein.

The term 'Licensed Products' shall mean products for the immunotherapy of prostate cancer which are produced by [  ***  ], with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP.

The term 'Licensed Processes' shall mean any process for the immunotherapy of prostate cancer in patients by [  ***  ] including, but not limited to [  ***  ], ex vivo, with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP, and [  ***  ] the use or practice of which would, but for the licenses granted herein, infringe one or more Valid Claims of an issued patent or pending patent application included in SKICR Patent Rights.

IPSCIO Record ID: 3789

License Grant
The Company entered into an agreement with Licensee, the former Board of Directors and as the Company’s President and Chief Scientific Officer, for certain patents regarding the molecular diagnostic technology platforms.
License Property
The patents cover highly predictive, metastic cancer molecular diagnostic test products, including the EP-CAM Detection Kit(TM).

These patents related to a proprietary technological product for the detection of epithelial cancer, referred to as the “EP-CAM Detection Kit.”

As a result of an acquisition, the Company now owns the rights to the following two (2) Greek patents and four (4) Greek patent applications
Greek Patent No. 1004303, issued November 6, 2002, entitled “Detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”
Greek Patent No. 1004765, issued December 22, 2004 – PCT-Pending, entitled “Detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”
Greek Patent Application No. 20040100269, dated July 2, 2004, entitled “Prototype RT and PCR protocols using Neowater and detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”

IPSCIO Record ID: 4690

License Grant
The Licensee agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology.
License Property
The non-exclusive license is to a worldwide portfolio of patents and patent applications directed to Diagnosis and Prognosis of Breast Cancer Patients (e.g., claiming priority to U.S. Provisional Patent Nos. 60/298918 and/or 60/380710) in the fields of research, diagnosis, prognosis and/or prediction of therapeutic outcome or risk for humans or animals in the area of oncology.

IPSCIO Record ID: 26489

License Grant
The Company hereby grants to Licensee an exclusive, worldwide, royalty-bearing, limited license under the Licensed Technology to make, have made, import, use, sell and have sold the Devices solely within the Field of Use.
License Property
U.S. 5,860,934                    Method and Device for Mechanical Imaging of Breast         Issued 01/19/99

(CIP of App. 07/994,109)

U.S. 5,833,633                    Device for Breast Haptic Examination                       Filed 11/03/97

(CIP of 5,524,636)                                                                           Issued 11/10/98

U.S. 5,785,633                    Method and Device for Mechanical Imaging of Prostate       Filed 02/27/96

(CIP of 5,524,636)                                                                           Issued 07/28/98

U.S. 5,836,894                    Apparatus for Measuring Mechanical Parameters of the       Filed 06/10/97

(CIP of 5,524,636)                Prostate and for Imaging the Prostate Using such           Issued 11/17/98

U.S. 5,922,018                    Method for Using a Transrectal Probe to Mechanically        Filed 06/10/97

(CIP of 5,524,636)                Image the Prostate Gland                                    Issued 07/13/99

U.S. 5,524,636                    Method and Apparatus for Elasticity Imaging                Filed 12/21/92

U.S. 5,265,612                    Intracavity Ultrasonic Device for Elasticity Imaging       Filed 12/21/92

U.S. 6,142,959                    Device for Palpation and Mechanical Imaging of the         Filed 07/22/99

                                  Prostate                                                   Issued 11/07/00

PCT/US00/19756                    Device for Palpation and Mechanical Imaging of the         Filed 07/21/00

                                  Prostate

U.S. 09/843,056                   Apparatus and Method for Mechanical Imaging of Breast      Filed 04/26/01

PCT/US01/13551                    Apparatus and Method for Mechanical Imaging of Breast      Filed 4/26/01

U.S. 60/200,433                   Apparatus and Method for Mechanical Imaging of Breast      Filed 4/28/00

U.S. 09/819,419                   Real Time Mechanical Imaging of the Prostate               Filed 03/28/01

Field of Use
Field of Use shall mean the diagnosis of and the treatment of (a) benign prostatic hyperplasia; (b) prostatitis; © prostate cancer; or (d) any other conditions of or disorders of the prostate, whether healthy or diseased, and any other condition of urologic disorder which may be diagnosed, imaged or treated using any diagnostic or imaging process.  Prostate imaging system and related patented technology.

IPSCIO Record ID: 27967

License Grant
Licensor, is willing to grant to the sublicensee a worldwide, nonexclusive, royalty-bearing sublicense to use such patent rights for the development and commercialization of Diagnostic Services, Licensed Reagents and Kits.  Certain patent rights including but not limited to screening, diagnosis, prognosis and monitoring tests, for the purpose of detecting changes associated with colorectal cancer, were licensed under the agreement dated as of February 5, 1992.
License Property
Diagnostic Service(s) shall mean the performance of laboratory-based assays covered in whole or in part by a Valid Claim of the Patent Rights.

U.S. Patent No. 5,352,775 & U.S.  Patent Application No.  08/861,910

Field of Use
Field shall mean the determination, in stool or samples prepared from stool, of the presence of, absence of or variation(s) within a nucleic acid of interest, or differences between a nucleic acid of interest and a reference standard or sample, including but not limited to screening, diagnosis, prognosis and monitoring tests, for the purpose of detecting changes associated with colorectal cancer.

IPSCIO Record ID: 383582

License Grant
In the original agreement, Licensor granted
— For the Layton and Stanford Patent Rights a nonexclusive, non-transferrable, limited sub-licensable, world-wide license under the Layton Patent Rights and the Stanford Patent Rights to practice and use the subject matter within the Layton Patent Rights and the Stanford Patent Rights in the Licensee Database Field of Use, Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Montefiore Patent Rights, a non-transferrable, limited sub-licensable, world-wide license under the Montefiore Patent Rights to practice and use the subject matter within the Montefiore Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Cancer Marker Patent Rights, Licensor grants a non-transferrable, limited sub-licensable, world-wide license under the Cancer Marker Patent Rights to practice and use the subject matter within the Cancer Marker Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use, only with respect to cancer.
— For the Database Patent Rights and Seilhamer/Scott Patent Rights, Licensor grants a nonexclusive, non-transferable, non-sublicensable , world-wide license under the Database Patent Rights and Seilhamer/Scott Patent Rights to practice and use the subject matter within the Database Patent Rights and the Seilhamer/Scott Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use.
— For the Sublicenses, Licensee shall have the right to grant sublicenses to third parties under such Patent Rights on a Product-by-Product basis to make, use, import, sell, and offer for sale Products developed by Licensee or its Affiliates.
— For the Co-Exclusive Licenses in the Homebrew and Diagnostic Fields of Use, Co-Exclusive shall mean that each Party has the right to exercise all of the rights under the Patent Rights in question in the field of use for which the parties have co-exclusive rights, without obligation to the other except to the extent provided in this Agreement, and neither Party alone has the right to grant sublicenses to third parties under such Patent Rights without express written consent of the other Party.
License Property
Cancer Marker Patent Rights shall mean all Valid Claims listed in any of the following patents and patent applications, to the extent that they are owned by Licensor with the right to license under this Agreement, and to the extent that they claim the composition of matter or use of any nucleic acids or proteins as markers or diagnostics for cancer.

The patents include
— Processes for Genetic Manipulations Using Promoters;
— Method for Detecting Pathological Conditions;
— Comparative Gene Transcript Analysis; and,
— Methods for Fabricating Micro Arrays of Biological Samples.

Field of Use
Licensee licenses various classes of patents from Licensor pertaining to the manipulation of genes, the detection of pathological conditions, comparative gene analysis, methods for fabricating tests of biological samples and the use of proteins as markers for cancers.

IPSCIO Record ID: 26038

License Grant
The Licensor grants to Licensee a non-exclusive right and license, without the right to sublicense, under the Licensed Patent Rights as licensed to Licensor pursuant to the Original Agreement, to make, have made, use, sell, offer for sale and import Licensed Products and to practice the Licensed Methods in the Field in the Territory to the extent permitted by law.
License Property
The Licensor is involved in the discovery, development and commercialization of medical tests that diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. Field shall mean in-vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.
Field of Use
The Licensee is a provider of clinical laboratory services.

Field” shall mean in vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.

IPSCIO Record ID: 369332

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses, under the Licensed Technology to use, sell, have sold, offer for sale, promote, market and advertise Licensed Solutions within the Field in the Territory.

Licensor grants a non-exclusive, non-transferable license to use and reproduce the Licensor Trademarks.

License Property
Licensor has developed and owns GeneRxâ„¢ Breast Cancer Profile, a laboratory developed multiple marker profile useful in the clinical prognosis of breast cancer.

The Licensor Algorithm is a mathematical equation that combines scored molecular markers and clinicopathologic features. The equation may be represented as one or more equations. The equation contains parameters used to relate specific biomarkers and/or sets of biomarkers to a relevant breast cancer outcome.

Licensors sciences markers are
IHC markers ER; PGR; ERBB2 (HER2/neu); BCL2; CDKN1B (p27/Kip1); EGFR; and, TP53
FISH marker MYC

Of these, the Pre-Screening Markers are ER, PGR, ERBB2 (HER2/neu), and, the Non-Standard Markers are BCL2, CDKN1B (p27/Kip1), EGFR, TP53 MYC.

The patents are titled Diagnostic markers predictive of outcomes in breast cancer treatment and progression and methods of use thereof.

The trademark is GeneRxTM.

Field of Use
Licensee's Insight(TM) Dx Breast Cancer Profile is a series of molecular assays that, when combined using Licensor' proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy. The profile could allow patients to avoid the toxic effects of unnecessary chemotherapy, thereby reducing the overall cost of care.

The Field shall mean the prognosis of breast cancers in the commercial reference laboratory space, which includes, without limitation, any facility or academic institution to the extent engaging in a commercial reference laboratory business.

IPSCIO Record ID: 5811

License Grant
The License Agreement grants us a non-exclusive, non-transferable and non-assignable License to use Licensor’s patents, trademarks and technology rights relating to the licensed products and the processing and reporting of laboratory analyses of samples collected using the products.
License Property
The products licensed are Cholesterol Panel; Hemoglobin A1c; Prostate Screen; Thyroid Test and Anemia Test.

Cholesterol Panel (a lipid profile consisting of total cholesterol, high density cholesterol, low density cholesterol and triglycerides).  This Cholesterol Panel is the first self-collected lipid profile for dried blood sample analysis that satisfies the National Cholesterol Education Program’s rigorous performance standards. It is used in the management and determination of coronary heart disease.

Hemoglobin A1c (a test that meets the certification standards of the National Glycohemoglobin Standardization Program). This test is critical for proper blood sugar monitoring and regulation by persons affected with diabetes.

Prostate Screen (a test to determine blood levels of prostate specific antigen). This test is used to help determine abnormal prostate conditions, such as prostate cancer.

Thyroid Test (a test to determine blood levels of thyroid stimulating hormone). This test is used to help determine thyroid dysfunction and to successfully manage treatment regimens.

Anemia Test (a rapid response test – like a home pregnancy test, the results are available to the user immediately – for low hemoglobin levels). This test is used to monitor and identify the onset or change in hemoglobin levels, which is a common side effect for many disease states including HIV, chronic kidney disease and cancer.

Field of Use
Products specialize in the use of micro-sample blood transportation devices and unique scientific procedures for the clinical testing of these micro-blood samples.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.